Language:
Banner
Relacje inwestorskie > Investors

A record-breaking year 2025 for Genomed S.A.

Genomed S.A. has published its results for 2025: a 26.6% increase in revenue, ROE of 24.1% and a 67% increase in sales of NGS services in the Life Science segment.
NEWS

Aktualnosci Inwestorzy

| Genomed S.A. ended 2025 with the best financial results in its history. The company significantly expanded the scale of its operations, improved profitability and strengthened its position as the leader of the Polish genomics and genetic diagnostics market, based on NGS technology. więcej »
aktualizacja: 26-05-2026 15:24:21


OUR DEBUT